Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Melanoma × Sodium Chloride × Clear all

Phase

Status

Recruiting 3 Completed 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 6 Leukemia, Myeloid, Acute 3 Carcinoma, Non-Small-Cell Lung 3 Neoplasms 2 Kidney Neoplasms 2 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Skin Neoplasms 1 Recurrence 1 Radiation Injuries 1 Prostatic Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precancerous Conditions 1 Pleural Effusion, Malignant 1 Platinum Resistant Ovarian Cancer 1 Ovarian Neoplasms 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Mycosis Fungoides 1 Melanoma 1 Lymphopenia 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Non-Hodgkin 1 Lymphoma, B-Cell, Marginal Zone 1 Lung Neoplasms 1 Hot Flashes 1 Hodgkin Disease 1 Gangliosidosis, GM1 1 Gangliosidoses 1 Fatigue 1

Interventions

pembrolizumab 45 Ipilimumab 39 Cyclophosphamide 38 Nivolumab 33 aldesleukin 26 fludarabine 19 Vemurafenib 19 Interleukin-2 19 dabrafenib 15 Temozolomide 15 fludarabine phosphate 13 trametinib 12 Radiosurgery 9 Dacarbazine 9 spartalizumab 8 cobimetinib 8 binimetinib 8 Radiotherapy 8 poly ICLC 6 encorafenib 6 Introns 6 CTLA-4 Antigen 6 Biopsy 6 montanide ISA 51 5 atezolizumab 4 Interferon alpha-2 4 Immunohistochemistry 4 Celecoxib 4 Bevacizumab 4 tovorafenib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03233828 2024-07-24

IL-2

Nova Scotia Health Authority

Phase 3 Terminated

1 enrolled 3 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡